I-MIBG PET/CT to Monitor Metastatic Disease in Children with Relapsed Neuroblastoma.

The metaiodobenzylguanidine (MIBG) scan is one of the most sensitive noninvasive lesion detection modalities for neuroblastoma. Unlike I-MIBG, I-MIBG allows high-resolution PET. We evaluated I-MIBG PET/CT for its diagnostic performance as directly compared with paired I-MIBG scans. Before I-MIBG therapy, standard I-MIBG imaging (5.2 MBq/kg) was performed on 7 patients, including whole-body (anterior-posterior) planar imaging, focused-field-of-view SPECT/CT, and whole-body I-MIBG PET/CT (1.05 MBq/kg). After therapy, 2 of 7 patients also completed I-MIBG PET/CT as well as paired I-MIBG planar imaging and SPECT/CT. One patient underwent I-MIBG PET/CT only after therapy. We evaluated all 8 patients who showed at least 1 I-MIBG-positive lesion with a total of 10 scans. In 8 pairs, I-MIBG and I-MIBG were performed within 1 mo of each other. The locations of identified lesions, the number of total lesions, and the curie scores were recorded for the I-MIBG and I-MIBG scans. Finally, for 5 patients who completed at least 3 PET/CT scans after administration of I-MIBG, we estimated the effective dose of I-MIBG. I-MIBG whole-body planar scans, focused-field-of-view SPECT/CT scans, and whole-body I-MIBG PET scans found 25, 32, and 87 total lesions, respectively. There was a statistically significant difference in lesion detection for I-MIBG PET/CT versus I-MIBG planar imaging ( < 0.0001) and I-MIBG SPECT/CT ( < 0.0001). The curie scores were also higher for I-MIBG PET/CT than for I-MIBG planar imaging and SPECT/CT in 6 of 10 patients. I-MIBG PET/CT demonstrated better detection of lesions throughout the body, including the chest, spine, head and neck, and extremities. The effective dose estimated for patient-specific I-MIBG was approximately 10 times that of I-MIBG; however, given that we administered a very low activity of I-MIBG (1.05 MBq/kg), the effective dose was only approximately twice that of I-MIBG despite the large difference in half-lives (100 vs. 13.2 h). The first-in-humans use of low-dose I-MIBG PET for monitoring disease burden demonstrated tumor detection capability superior to that of I-MIBG planar imaging and SPECT/CT.